What Tagi Pharma does

Tagi Pharma, Inc. is a specialty pharmaceutical company that develops, licenses, and distributes generic drug products. Founded in 2010 as a wholly owned subsidiary of Precision Dose, Inc. (established 2003), the company was created to penetrate the Retail Market Segment by exploiting the shift in care delivery from hospitals and physician offices to retail drug chains, food chains, clinics, and 24-hour walk-in medical facilities. Its current product portfolio consists of generic oral tablets and capsules in blister packaging — including azithromycin tablets and benzonatate capsules — with a pipeline of injectable products in development. The company has converted its product catalog to Precision Dose's product offerings and routes buyers to the parent company's site, signaling close operational integration with Precision Dose's institutional line.

Tagi operates an asset-light model. Manufacturing and development are executed through a network of contract manufacturing organizations (CMOs), contract development organizations (CDMOs), and contract research organizations (CROs), with portfolio growth driven by ANDA acquisitions, licensing, and co-development partnerships. Tagi's go-to-market is sales-led: an experienced sales organization services retail drug chains, food chains, and institutional customers, and conducts physician office visits to promote specific products. The company leverages Precision Dose's warehouse and administrative infrastructure and pre-existing relationships with Hospital and Long Term Care customers to reach institutional accounts.

Commercially, Tagi generates revenue through one-time product sales of generic pharmaceuticals across Retail and Institutional Market Segments. Pricing is not publicly disclosed and is expected to be negotiated B2B. The company is privately held, headquartered in South Beloit, Illinois, with 11-50 employees. No external institutional investors or public listings are disclosed, and the company is operationally tightly coupled with its parent, Precision Dose, Inc.

Name

Tagi Pharma

Legal name

TAGI Pharma, Inc.

Website

https://tagipharma.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Tagi Pharma is a specialty generic pharmaceutical company and wholly owned subsidiary of Precision Dose, Inc. It develops, licenses, and distributes generic oral tablets, capsules, and pipeline injectables to retail drug chains, clinics, and institutional healthcare customers.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industry

Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)

Keywords

• Generic pharmaceuticals
• Retail pharmacy distribution
• Institutional drug supply
• Oral solid dosage
• Specialty drug distribution

Headquarters

HQ city

South Beloit

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceutical Product Sales: TAGI Pharma generates revenue through the sale of generic pharmaceutical products including unit dose liquid cups, oral syringes, blister-packaged oral tablets and capsules. The company acquires, licenses, and co-develops products to expand its portfolio and drive sales across Retail and Institutional Market Segments.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Core offering

TAGI Pharma is a specialty pharmaceutical company that manufactures, acquires, licenses, and co-develops generic pharmaceutical products—including oral tablets and capsules in blister packaging, with injectable products in development. The company distributes these products through direct sales to retail drug chains, food chains, retail pharmacies, clinics, walk-in 24-hour medical facilities, hospitals, and long-term care facilities across the U.S. Retail and Institutional Market Segments.

Product overview

TAGI Pharma is a specialty pharmaceutical company offering generic pharmaceutical products. The company operates as a wholly owned subsidiary of Precision Dose, Inc. and has converted its product portfolio to Precision Dose's product offerings. Current products include generic oral tablets and capsules in blister packaging, with injectable products in development. The company leverages its parent company's warehouse and administrative infrastructure, along with established relationships with Hospital and Long Term Care customers, to serve both Retail and Institutional Market Segments.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Oral Tablets and Capsules in Blister Packaging Core retail product line consisting of generic oral tablets and capsules supplied in blister packaging. Targeted at retail drug chains, food chains, retail pharmacies, clinics, and walk-in 24-hour medical facilities, the line has been converted to parent company Precision Dose's product offerings.
• Injectable Products (Pipeline) Future line of injectable pharmaceutical products in development, intended to expand Tagi Pharma's portfolio beyond oral solid dosage forms and serve both retail and institutional healthcare customers.

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• Contract Manufacturing Organizations (CMOs)coreStrategic or Co-development PartnerTAGI Pharma has established a network of quality-focused contract manufacturing organizations for its products. These partnerships support the company's product quality and supply chain reliability for generic pharmaceutical manufacturing.
• Contract Development Organizations (CDOs/CROs)coreStrategic or Co-development PartnerTAGI Pharma partners with contract development organizations to support product development activities. The company seeks CDMOs, CMOs, and CROs specializing in niche products of any therapeutic class and final dosage form.
• License and Development PartnerscoreStrategic or Co-development PartnerTAGI Pharma continues to seek license and development partners for specializing in niche products of any therapeutic class and final dosage form. The company has experienced extraordinary growth through partnering with ANDA acquisitions, licensing, and co-development of products.
• Precision Dose, Inc.coreOEM/ Whitelabel/ Licensing PartnerTAGI Pharma is a wholly owned subsidiary of Precision Dose, Inc. The company leverages Precision Dose's established relationships with Hospital and Long Term Care customers, as well as Precision Dose's warehouse and administrative infrastructure. TAGI Pharma's product portfolio has converted to Precision Dose's product offerings.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• ANI Pharmaceuticals: ANI Pharmaceuticals is a U.S. specialty generic pharmaceutical company focused on niche ANDAs across multiple therapeutic areas. Like TAGI, ANI pursues a niche-generic strategy and commercializes through both retail and institutional channels.
• Lannett Company: Lannett is a U.S. generic pharmaceutical developer and manufacturer with a broad oral solid and specialty portfolio sold to retail, institutional, and government channels. Its niche/specialty generic orientation and product-acquisition-driven growth model closely mirror TAGI's stated approach.
• Upsher-Smith Laboratories: Upsher-Smith is a U.S. specialty generic and branded pharmaceutical company that develops, licenses, and distributes generic and brand products across retail and institutional channels. Its mix of in-licensed and co-developed generics parallels TAGI's licensing and co-development model.
• Padagis: Padagis is a U.S. specialty generic pharmaceutical company that develops, manufactures, and distributes generic prescription products across multiple therapeutic areas. Its specialty-generic, multi-channel model makes it a close comparable to TAGI.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a deep U.S. ANDA portfolio spanning retail, hospital, and specialty channels. It is a broad incumbent that competes with TAGI in many of the same generic molecules, particularly in retail pharmacy.
• Aurobindo Pharma USA: Aurobindo's U.S. business is one of the largest generic pharmaceutical suppliers to U.S. retail and institutional channels, with a broad ANDA portfolio. It competes with TAGI across oral generics, but at materially greater scale and breadth.
• Apotex: Apotex is a large global generic pharmaceutical manufacturer with a substantial U.S. ANDA portfolio across retail and institutional channels. It is a broader incumbent that competes with TAGI's generic offerings in many of the same therapeutic classes.
• Endo International (Par Pharmaceutical): Endo's Par Pharmaceutical segment is a major U.S. generic manufacturer with a portfolio spanning oral solids, injectables, and specialty. It overlaps with TAGI's retail/institutional generic focus and dose-form breadth, but at significantly larger scale.
• Sandoz (Novartis): Sandoz is a global leader in generic pharmaceuticals with a broad U.S. portfolio across retail and institutional channels, including injectables. It is a broad incumbent that competes with TAGI's current and pipeline products but at vastly greater scale.
• Amneal Pharmaceuticals: Amneal is a large U.S.-focused generic and specialty pharmaceutical company with a broad ANDA portfolio across retail, institutional, and injectables. It is comparable to TAGI as a generic-ANDA competitor but operates at substantially greater scale across more therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tagi-pharma-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tagi Pharma